TSX futures inch lower after index falls for third straight session

U.S. markets extended losses for a third session, driven by robust economic data, including an upward Q2 GDP revision, which is dampening expectations for significant Federal Reserve rate cuts ahead of crucial PCE inflation data. Concurrently, President Trump announced new tariffs, notably a 100% levy on certain pharmaceutical products, while a reported potential White House policy requiring U.S. tech firms to match domestic semiconductor output with imports or face tariffs signals significant future disruption for global tech supply chains and foreign competitors. Oil prices are also poised for weekly gains amid tightening supply.

Analysis

U.S. markets are exhibiting heightened caution, extending losses for a third consecutive session as robust economic data tempers expectations for Federal Reserve rate cuts. An upward revision to second-quarter GDP and a decline in weekly jobless claims have shifted investor focus to the upcoming PCE price index, the Fed's preferred inflation gauge, although its impact may be limited ahead of next week's jobs report. Concurrently, new trade policies from the Trump administration are creating significant sector-specific volatility. A 100% tariff on select imported pharmaceutical products directly threatens firms like Johnson & Johnson, Pfizer, and Eli Lilly, unless they commit to building U.S. manufacturing facilities. In the technology sector, a potential policy requiring U.S. firms to match domestic semiconductor output with imports is creating a tailwind for domestic producers like Intel, while posing a substantial risk to foreign chip suppliers. In commodities, oil prices are set for a weekly gain of approximately 4%, reflecting a tightening market due to attacks on Russian energy infrastructure and a surprise drop in U.S. crude inventories.

Key Decisions for Investors

• Re-evaluate semiconductor holdings, as the proposed U.S. policy to favor domestic production creates a clear long-term tailwind for companies like Intel while presenting significant risk for foreign chip suppliers.
• Investors in global pharmaceutical companies such as Pfizer, Johnson & Johnson, and Eli Lilly should scrutinize their exposure to import tariffs and monitor any strategic shifts towards onshoring manufacturing in the U.S.
• Maintain a defensive posture on broad market indices, as strong economic data reduces the likelihood of Fed rate cuts, and await the upcoming PCE and jobs data for clearer signals on monetary policy direction.